Clinical Trial Update: CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) [Phase 1]

View source ↗

Summary

A Phase 1 trial update indicates recruitment for Senza5 CART5, CD5-deleted CAR T cells, targeting T-cell non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Senza5 CART5 (CD5-deleted chimeric antigen receptor T cells)

Snippet

Sponsor: Vittoria Biotherapeutics | Conditions: T Cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING